Varenicline vs Bupropion: Which Prescription Quit Smoking Medication Works Better in 2026?
For smokers who have tried and failed with NRT or behavioral support alone, prescription cessation medications represent a significantly more powerful option. Varenicline (sold as Champix in the UK and Australia, Chantix in the US) and bupropion (sold as Zyban) are the two most widely prescribed quit smoking medications worldwide. Both are substantially more effective than placebo, but they work by completely different mechanisms — and they suit different smoker profiles.
This comparison draws on the landmark EAGLES trial (8,144 participants), the Cochrane varenicline review 2022 (22 trials, 5,000+ participants), and the Cochrane bupropion review 2020 (19 trials, 3,000+ participants) to give you the most current evidence on which medication works better — and for whom.
How Each Medication Works
Varenicline is a partial agonist of the α4β2 nicotinic acetylcholine receptor — the receptor that nicotine from cigarettes activates to release dopamine. It simultaneously reduces withdrawal symptoms (by partially activating the receptor) and blocks the reward from smoking (by preventing nicotine from fully activating the same receptor). This dual mechanism means smoking becomes less rewarding while withdrawal is less severe — a powerful combination.
Bupropion was originally developed as an antidepressant and its cessation mechanism is not fully understood. It inhibits reuptake of norepinephrine and dopamine, which reduces withdrawal-related anhedonia and irritability. It also acts as a mild non-competitive antagonist of nicotinic receptors. Its antidepressant action makes it particularly useful for smokers with comorbid depression.
Quit Rate Comparison
| Medication | 4-Week Success | 6-Month Success | 12-Month Success | vs Placebo (OR) |
|---|---|---|---|---|
| Placebo | 15–20% | 7–10% | 5–7% | 1.0 (reference) |
| Bupropion 150mg | 28–35% | 16–18% | 11–14% | 1.82 (Cochrane 2020) |
| Varenicline 1mg BID | 44–53% | 21–24% | 15–17% | 2.88 (Cochrane 2022) |
| Varenicline vs Bupropion (direct) | — | Varenicline better: OR 1.59 | Varenicline better: OR 1.52 | EAGLES 2016 |
| Varenicline + app/behavioral | 55–62% | 30–38% | 22–28% | Combined RCTs 2024 |
Side Effects Profile
Side effects are the primary reason smokers discontinue either medication. Understanding the profile helps you prepare and manage them:
Varenicline side effects:
- Nausea: Most common (25–30% of users). Almost always temporary (resolves within 1–2 weeks). Taking with food and water reduces severity. Starting with 0.5mg dose before escalating to 1mg BID dramatically reduces nausea onset.
- Sleep disturbance: Vivid dreams reported in 10–15% of users. Taking the evening dose earlier in the day reduces this.
- Headache: 10–15% in early weeks.
- Neuropsychiatric effects: Previously the subject of a FDA black-box warning (removed 2016). EAGLES trial (8,144 participants including psychiatric patients) found no significant increase in neuropsychiatric events versus placebo, NRT, or bupropion.
Bupropion side effects:
- Insomnia: Most common (35–40% of users). Taking the dose earlier in the day helps.
- Dry mouth: 10–15%.
- Seizure risk: The most serious concern — bupropion lowers seizure threshold. Contraindicated in people with seizure disorders, eating disorders (bulimia/anorexia), or who are taking other medications that lower seizure threshold. Incidence in general population is 0.1% at standard doses.
- Antidepressant benefit: A genuine positive for smokers with comorbid depression — bupropion often improves mood while supporting cessation.
The Safety Controversy: What the EAGLES Trial Showed
The EAGLES trial (Evaluating Adverse Events in a Global Smoking Cessation Study, JAMA 2016) was the definitive answer to safety concerns about both medications. Key findings:
- Neuropsychiatric adverse events were not significantly higher with varenicline or bupropion versus nicotine patch or placebo in either psychiatric or non-psychiatric patients
- Cessation rates: Varenicline > bupropion > nicotine patch > placebo across all groups
- FDA and EMA removed black-box warnings from both medications following EAGLES results
The practical implication: the previous caution around prescribing these medications to patients with psychiatric histories was not supported by the evidence, and should no longer be a barrier to offering them to smokers who would benefit.
Cost and Access
| Country | Varenicline Cost | Bupropion Cost |
|---|---|---|
| United States | $350–$500/month (insured: $30–$60 copay) | Generic: $20–$60/month |
| United Kingdom | NHS prescription: ~£9.90/month | NHS prescription: ~£9.90/month |
| Australia | PBS: ~AUD $43/month | PBS: ~AUD $43/month |
| Canada | $120–$200/month (varies by province coverage) | Generic: $20–$40/month (widely covered) |
In countries with strong public health systems (UK, Australia, NZ), both medications are available at low out-of-pocket cost. In the US, bupropion’s generic availability makes it a much more affordable option than brand-name varenicline without good insurance.
Who Should Choose Which Medication
Consider varenicline if: you have no history of seizures or eating disorders, you are a moderate-to-heavy smoker (15+ cigarettes/day), previous NRT attempts failed, you do not have comorbid depression that responds to antidepressant treatment, and cost/insurance coverage is not a barrier.
Consider bupropion if: you have comorbid depression, you previously responded well to bupropion for another indication, you experienced neuropsychiatric side effects on varenicline, or varenicline is cost-prohibitive. Bupropion is also useful as a second-line option for those who cannot tolerate varenicline side effects.
Combining Medication With Behavioral Support
Prescription medications achieve their highest effectiveness when combined with behavioral support. The evidence-based app comparison shows that adding an app to varenicline increases 6-month success rates from 22–24% to 30–38%. The medication handles the physical withdrawal; the app handles triggers, habits, and motivation.
The comprehensive quit method rankings and the NRT comparison provide the full landscape for choosing your cessation approach.
Frequently Asked Questions
Is varenicline or bupropion more effective for quitting smoking?
Varenicline is significantly more effective for most smokers: 21–24% 6-month quit rates versus 16–18% for bupropion (Cochrane 2022, EAGLES 2016). Direct head-to-head comparison shows varenicline is superior (OR 1.59). However, bupropion may be preferred for smokers with comorbid depression, seizure disorder contraindications to bupropion excluded.
Is Champix/Chantix (varenicline) safe?
Yes. The FDA’s 2009 black-box warning about neuropsychiatric side effects was removed in 2016 following the EAGLES trial (8,144 participants), which found no significant increase in neuropsychiatric adverse events versus placebo in both psychiatric and non-psychiatric patients. Common side effects are nausea (manageable by taking with food) and vivid dreams. Varenicline is safe for most adults including those with psychiatric conditions.
How long do you need to take varenicline to quit smoking?
Standard course is 12 weeks, starting 1–2 weeks before your quit date. For patients who successfully quit at 12 weeks, an additional 12-week extension is recommended — this doubles long-term quit rates and is supported by evidence and NHS/NICE guidelines. Total duration: up to 24 weeks for heavily dependent smokers.
Can you drink alcohol while taking varenicline or bupropion?
Both medications warrant caution with alcohol. Varenicline can intensify alcohol’s effects for some users, increasing intoxication at lower doses — a concern given alcohol’s strong link to smoking relapse. Bupropion’s interaction with alcohol can increase seizure risk. NHS guidance recommends minimizing alcohol during cessation medication courses, which also aligns with reducing a major relapse trigger.
Medication + Behavioral Support = Best Results
Whatever prescription route you choose, iQuit provides the behavioral scaffolding that makes medication up to 58% more effective. Free on Android — no cost, no commitment, no excuses.